Brokerages predict that Insmed Incorporated (NASDAQ:INSM) will post $5.01 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Insmed’s earnings. The lowest sales estimate is $2.20 million and the highest is $9.80 million. The company is scheduled to report its next quarterly earnings report on Friday, February 22nd.
According to Zacks, analysts expect that Insmed will report full-year sales of $6.05 million for the current financial year, with estimates ranging from $2.20 million to $9.80 million. For the next financial year, analysts forecast that the firm will report sales of $44.79 million, with estimates ranging from $36.70 million to $52.73 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Insmed.
Get Insmed alerts:
INSM has been the topic of several recent research reports. BidaskClub raised Insmed from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. ValuEngine cut Insmed from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 5th. Citigroup decreased their price objective on Insmed from $29.00 to $22.00 and set a “neutral” rating on the stock in a report on Tuesday, December 4th. Canaccord Genuity upped their price objective on Insmed from $20.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 15th. They noted that the move was a valuation call. Finally, Zacks Investment Research raised Insmed from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Tuesday, January 22nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $33.57.
In related news, Director Melvin Md Sharoky purchased 8,795 shares of the firm’s stock in a transaction that occurred on Monday, November 12th. The shares were bought at an average price of $15.59 per share, for a total transaction of $137,114.05. Following the acquisition, the director now owns 231,794 shares of the company’s stock, valued at approximately $3,613,668.46. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alfred Altomari sold 5,500 shares of the stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $25.00, for a total value of $137,500.00. Following the sale, the director now owns 36,942 shares in the company, valued at approximately $923,550. The disclosure for this sale can be found here. Corporate insiders own 3.88% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in INSM. Baker BROS. Advisors LP raised its holdings in Insmed by 164.6% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,851,982 shares of the biopharmaceutical company’s stock valued at $37,447,000 after buying an additional 1,151,982 shares during the period. Point72 Asset Management L.P. purchased a new stake in Insmed during the 3rd quarter valued at $13,129,000. JPMorgan Chase & Co. raised its holdings in Insmed by 91.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 506,391 shares of the biopharmaceutical company’s stock valued at $10,240,000 after buying an additional 241,921 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Insmed in the third quarter worth $4,396,000. Finally, Emerald Mutual Fund Advisers Trust increased its stake in Insmed by 34.2% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 845,858 shares of the biopharmaceutical company’s stock worth $17,103,000 after purchasing an additional 215,743 shares during the period.
Shares of INSM traded up $0.19 during mid-day trading on Tuesday, hitting $24.90. 363,898 shares of the stock were exchanged, compared to its average volume of 907,417. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -8.62 and a beta of 2.91. Insmed has a 52-week low of $11.31 and a 52-week high of $31.58. The company has a debt-to-equity ratio of 1.07, a current ratio of 10.06 and a quick ratio of 10.06.
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
Recommended Story: What are trading strategies for the 52-week high/low?
Get a free copy of the Zacks research report on Insmed (INSM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com